Table 1

Prevention of breast cancer by Arz in combination with LG268

TreatmentaNo. of tumor-free rats/total no. of rats (P1; P2)bAverage no. of tumors (P1; P2)ATBc (P1; P2)Rats with 3 or more tumors (P1; P2)Rats with tumor burden > 5 g (P1; P2)
Control (vehicle)2/243.413.317/2416/24
Arz (1)d6/12 (0.009)0.9 (0.01)2.2 (0.002)2/12 (0.004)1/12 (0.001)
Arz (0.5)0/122.06.54/127/12
LG268 (500)5/12 (0.03)0.8 (0.001)1.2 (0.005)0/12 (<0.0001)1/12 (0.001)
LG268 (100)6/12 (0.009)0.8 (0.002)1.1 (0.001)1/12 (0.0009)1/12 (0.001)
LG268 (30)3/121.7 (0.04)4.13/12 (0.01)2/12 (0.01)
Arz (1)+ LG268 (100)10/12 (<0.0001; 0.2)0.2 (0.002; 0.1)0.4 (0.002; 0.2)0/12 (<0.0001; 0.5)0/12 (0.0002; 1.0)
Arz (1)+ LG268 (30)7/12 (0.003; 1.0)0.6 (0.004; 0.4)1.4 (0.005; 0.9)1/12 (0.0009; 1.0)1/12 (0.001; 1.5)
Arz (0.5)+ LG268 (100)10/12 (<0.0001; <0.0001)0.3 (0.002; 0.001)0.1 (0.001; 0.0005)0/12 (<0.0001; 0.09)0/12 (0.0002; 0.005)
Arz (0.5)+ LG268 (30)3/12 (0.3; 0.2)1.3 (0.006; 0.3)2.4 (0.005; 0.02)1/12 (0.0009; 0.3)2/12 (0.01; 0.09)
  • a All rats (21 days old) received NMU (50 mg/kg, i.p.) 1 week before starting the feeding of chemopreventive agents and were autopsied 10 weeks later.

  • b P1 is the value for the comparison of rats treated with chemopreventive agents with control rats treated with vehicle alone; P2 is the value for the comparison of rats treated with Arz + LG268 with rats treated with Arz alone.

  • c ATB, average tumor burden (average weight in grams of a rat’s tumor at autopsy).

  • d All doses are shown as mg/kg diet.